BR112023005783A2 - Peptídeos e métodos de uso - Google Patents
Peptídeos e métodos de usoInfo
- Publication number
- BR112023005783A2 BR112023005783A2 BR112023005783A BR112023005783A BR112023005783A2 BR 112023005783 A2 BR112023005783 A2 BR 112023005783A2 BR 112023005783 A BR112023005783 A BR 112023005783A BR 112023005783 A BR112023005783 A BR 112023005783A BR 112023005783 A2 BR112023005783 A2 BR 112023005783A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- methods
- peptide
- synthetic
- neutrophils
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 230000004154 complement system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 230000006320 pegylation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
PEPTÍDEOS E MÉTODOS DE USO. A presente invenção fornece peptídeos que são modificações sintéticas do peptídeo Polar Assortant (PA), incluindo PEGuilação C-terminal. A invenção fornece ainda métodos de uso de pelo menos um peptídeo sintético para regular o sistema complemento e interagir com neutrófilos para alterar sua ligação e atividade.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063085556P | 2020-09-30 | 2020-09-30 | |
| US202163185831P | 2021-05-07 | 2021-05-07 | |
| PCT/US2021/052174 WO2022072272A2 (en) | 2020-09-30 | 2021-09-27 | Peptides and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023005783A2 true BR112023005783A2 (pt) | 2023-04-25 |
Family
ID=80951791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023005783A BR112023005783A2 (pt) | 2020-09-30 | 2021-09-27 | Peptídeos e métodos de uso |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240010681A1 (pt) |
| EP (1) | EP4222168A2 (pt) |
| JP (1) | JP2023548001A (pt) |
| KR (1) | KR20230078733A (pt) |
| AU (1) | AU2021355358A1 (pt) |
| BR (1) | BR112023005783A2 (pt) |
| CA (1) | CA3193565A1 (pt) |
| IL (1) | IL301441A (pt) |
| MX (1) | MX2023003700A (pt) |
| WO (1) | WO2022072272A2 (pt) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2297197B1 (en) * | 2008-05-29 | 2012-03-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof |
| KR20220104268A (ko) * | 2018-01-09 | 2022-07-26 | 레알타 홀딩스, 엘엘씨 | 동물 모델에서의 미엘로퍼옥시다제 산화 활성의 pic1 억제 |
-
2021
- 2021-09-27 JP JP2023520207A patent/JP2023548001A/ja active Pending
- 2021-09-27 MX MX2023003700A patent/MX2023003700A/es unknown
- 2021-09-27 EP EP21876258.1A patent/EP4222168A2/en active Pending
- 2021-09-27 WO PCT/US2021/052174 patent/WO2022072272A2/en active Application Filing
- 2021-09-27 US US18/029,206 patent/US20240010681A1/en active Pending
- 2021-09-27 BR BR112023005783A patent/BR112023005783A2/pt unknown
- 2021-09-27 CA CA3193565A patent/CA3193565A1/en active Pending
- 2021-09-27 IL IL301441A patent/IL301441A/en unknown
- 2021-09-27 KR KR1020237014144A patent/KR20230078733A/ko unknown
- 2021-09-27 AU AU2021355358A patent/AU2021355358A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023003700A (es) | 2023-04-21 |
| CA3193565A1 (en) | 2022-04-07 |
| JP2023548001A (ja) | 2023-11-15 |
| IL301441A (en) | 2023-05-01 |
| KR20230078733A (ko) | 2023-06-02 |
| WO2022072272A2 (en) | 2022-04-07 |
| AU2021355358A1 (en) | 2023-06-08 |
| US20240010681A1 (en) | 2024-01-11 |
| EP4222168A2 (en) | 2023-08-09 |
| WO2022072272A3 (en) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021026376A2 (pt) | Proteínas de fusão flt3l-fc e métodos de uso | |
| CO2019003809A2 (es) | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso | |
| CO2021003724A2 (es) | Proteínas de fijación a sirpα y métodos de uso de estas | |
| BR112022017930A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
| AR123115A1 (es) | Composiciones y métodos para la degradación selectiva de proteínas | |
| UY37928A (es) | Anticuerpos anti-cd38 y métodos de uso | |
| AR115418A1 (es) | ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS | |
| PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
| EA201592006A1 (ru) | Новые биспецифические связывающие молекулы с противоопухолевой активностью | |
| PE20170503A1 (es) | Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso | |
| CO2018013104A2 (es) | Polipéptidos de fusión cd40l-fc y sus métodos de uso | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| CL2021003580A1 (es) | Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso | |
| EP3939606A3 (en) | Improved methods and compounds for eliminating immune responses to therapeutic agents | |
| BR112019011860A2 (pt) | proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune | |
| CO2020010269A2 (es) | Variantes fc con unión mejorada a fcrn y semivida prolongada | |
| MX2022000367A (es) | Heterodimeros, metodos y uso de los mismos. | |
| NZ756224A (en) | Polypeptide variants and uses thereof | |
| EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| BR112021024938A2 (pt) | Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso | |
| BR112022009602A2 (pt) | Anticorpos anti-cd79 ch38c-cd79 chctric, células car-t, e usos dos mesmos | |
| AR115695A1 (es) | Moléculas proteicas multifuncionales que comprenden decorina y uso de estas | |
| MX2017010359A (es) | Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). | |
| BR112021017703A8 (pt) | Receptores de células t wt1 de alta avidez e usos dos mesmos |